10X Genomics Inc
Prices are adjusted according to historical splits.
- Today's Low:
- Today's High:
- Open Price:
- 52W Low:
- 52W High:
- Prev. Close:
- Market Cap.:
- $6.35 billion
- Book Value:
- Revenue TTM:
- $568.41 million
- Operating Margin TTM:
- Gross Profit TTM:
- $396.02 million
- Profit Margin:
- Return on Assets TTM:
- Return on Equity TTM:
10X Genomics Inc had its IPO on 2019-09-12 under the ticker symbol TXG.
The company operates in the Healthcare sector and Health Information Services industry. 10X Genomics Inc has a staff strength of 1,243 employees.
Shares of 10X Genomics Inc opened at $47.24 at the start of the last trading session i.e. 2023-09-12.
The stocks traded within a range of $47.24 - $49.76, and closed at $49.63.
This is a +3.4% increase from the previous day's closing price.
A total volume of 780,547 shares were traded at the close of the day’s session.
In the last one week, shares of 10X Genomics Inc have slipped by -8.18%.
10X Genomics Inc's Key Ratios
10X Genomics Inc has a market cap of $6.35 billion, indicating a price to book ratio of 5.1581 and a price to sales ratio of 8.1308.
In the last 12-months 10X Genomics Inc’s revenue was $568.41 million with a gross profit of $396.02 million and an EBITDA of $-149338000. The EBITDA ratio measures 10X Genomics Inc's overall financial performance and is widely used to measure its profitability.
In the trailing 12-month period, 10X Genomics Inc’s operating margin was -31.39% while its return on assets stood at -11.2% with a return of equity of -21.85%.
In Q2, 10X Genomics Inc’s quarterly earnings growth was a positive 0% while revenue growth was a positive 28.1%.
10X Genomics Inc’s PE and PEG Ratio
- Forward PE
- Trailing PE
Its diluted EPS in the last 12-months stands at $-1.56 per share while it has a forward price to earnings multiple of 196.0784 and a PEG multiple of . A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.
The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into 10X Genomics Inc’s profitability.
10X Genomics Inc stock is trading at a EV to sales ratio of 7.2373 and a EV to EBITDA ratio of -28.2318. Its price to sales ratio in the trailing 12-months stood at 8.1308.
10X Genomics Inc stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.
Balance sheet and cash flow metrics
- Total Assets
- $989.64 million
- Total Liabilities
- $98.09 million
- Operating Cash Flow
- Capital Expenditure
- $25.36 million
- Dividend Payout Ratio
10X Genomics Inc ended 2023 with $989.64 million in total assets and $0 in total liabilities. Its intangible assets were valued at $989.64 million while shareholder equity stood at $793.30 million.
10X Genomics Inc ended 2023 with $0 in deferred long-term liabilities, $98.09 million in other current liabilities, 2000.00 in common stock, $-1142482000.00 in retained earnings and $4.51 million in goodwill. Its cash balance stood at $325.88 million and cash and short-term investments were $391.39 million. The company’s total short-term debt was $9,286,000 while long-term debt stood at $0.
10X Genomics Inc’s total current assets stands at $582.94 million while long-term investments were $0 and short-term investments were $65.51 million. Its net receivables were $87.69 million compared to accounts payable of $23.12 million and inventory worth $83.69 million.
In 2023, 10X Genomics Inc's operating cash flow was $-4462000.00 while its capital expenditure stood at $25.36 million.
Comparatively, 10X Genomics Inc paid $0 in dividends in 2023.
Other key metrics
- Current Trading Price
- 52-Week High
- 52-Week Low
- Analyst Target Price
10X Genomics Inc stock is currently trading at $49.63 per share. It touched a 52-week high of $63.57 and a 52-week low of $63.57. Analysts tracking the stock have a 12-month average target price of $62.75.
Its 50-day moving average was $54.04 and 200-day moving average was $49.41 The short ratio stood at 4.9 indicating a short percent outstanding of 0%.
Around 245.7% of the company’s stock are held by insiders while 9254.2% are held by institutions.
Frequently Asked Questions About 10X Genomics Inc
Similar Industry Stocks (Health Information Services)
10x Genomics, Inc., a life science technology company, develops and sells instruments, consumables, and software for analyzing biological systems in North America, Europe, the Middle East, Africa, China, and the Asia Pacific. The company provides chromium and chromium connect instruments, microfluidic chips, slides, reagents, and other consumables products. Its single cell solutions runs on its chromium instruments, which include single cell gene expression for measuring gene activity on a cell-by-cell basis; single cell immune profiling for measuring the activity of immune cells and their targets; single cell Assay for Transposase Accessible Chromati (ATAC) for measuring epigenetics comprising the physical organization of DNA; and single cell multiome ATAC + gene expression for measuring the genetic activity and epigenetic programming in the same cells across tens of thousands of cells in a single experiment. The company also provides visium spatial gene expression solution for measuring spatial gene expression patterns across a single tissue sample or gene expression and protein co-detection when combined with immunofluorescence. It serves various academic, government, biopharmaceutical, biotechnology, and other institutions. The company was formerly known as 10X Technologies, Inc. and changed its name to 10x Genomics, Inc. in November 2014. 10x Genomics, Inc. was incorporated in 2012 and is headquartered in Pleasanton, California.